Guillermo Garcia-Manero, MD, Shares Recent Progress in Low-Risk MDS

Dr. Garcia-Manero, a Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, discusses the latest progress in treating low-risk myelodysplastic syndromes (MDS) at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain.

“We are developing a number of very effective compounds,” he said, beginning with luspatercept. The first-in-class drug is used both in the first- and second-line setting for patients with transfusion-dependent, low-risk MDS and anemia.

“Compared to an [erythropoiesis-stimulating agent], this drug improves the response rates and duration of response in the frontline setting,” Dr. Garcia-Manero explained.  “We’re gaining a lot more knowledge in terms of the quality of those responses and the outcomes of patients [who] respond to therapy.”